- Trade Name: Vitrakvi (Loxo Oncology Inc)
- Indications: indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
- Class: Kinase inhibitor, Tropomyosin receptor kinase inhibitor
- Half-life: 2.9 hours
- FDA Approval Date: 11/26/2018
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: can cause embryo-fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
